berberine

Overview

Berberine (BBR) is a naturally occurring isoquinoline alkaloid belonging to the protoberberine class, found in several medicinal plants including Berberis, Coptis chinensis, and Coscinium fenestratum. It is characterized by a distinctive yellow color and a quaternary ammonium structure that enables intercalation into nucleic acids, binding to G-quadruplex (G4) DNA structures, and interaction with a broad spectrum of protein targets. Historically significant in traditional Asian medicine for its antimicrobial and anti-inflammatory properties, berberine has attracted sustained scientific attention for its pleiotropic pharmacological effects spanning metabolic regulation, anti-inflammatory signaling, and antineoplastic activity.

Mechanistically, berberine modulates multiple oncogenic and inflammatory cascades including the PI3K/Akt signaling pathway, the β-catenin/TCF4 axis, nuclear factor kappa B (NF-κB) signaling, and the CD44/JAK2/STAT3 signaling pathway. Its ability to intercalate into DNA and compete for nucleic acid-binding sites makes it a structurally versatile scaffold for targeting both protein–DNA and protein–protein interactions relevant to cancer and infectious disease. These properties, combined with a favorable safety profile relative to synthetic chemotherapeutics, have positioned berberine as a compound of significant translational interest across oncology, immunology, and antiviral research.

Focus of Latest Publications

Recent publications have continued to examine berberine as a bioactive compound with broad therapeutic potential, especially in metabolic, neurodegenerative, inflammatory, and cancer-related settings. In a mouse model of hyperglycemia-induced neurodegeneration, berberine was investigated for its neuroprotective effects and was proposed to act through modulation of Nrf2 expression. A separate Alzheimer’s-focused formulation study developed a berberine-loaded nanoemulsion for intranasal nose-to-brain delivery, reporting improved brain targeting, reduced reactive oxygen species, restoration of mitochondrial membrane potential in SH-SY5Y cells, and behavioral improvement in scopolamine-induced cognitive, depressive, and motor deficits.

Several studies also explored berberine in cancer and cell survival pathways. In colorectal cancer cells, berberine dose-dependently inhibited viability, promoted apoptosis, and suppressed DNA damage repair by upregulating SOX17 and inactivating the β-catenin/TCF4 pathway, with PIM3 identified as a downstream mediator. In an Ehrlich ascites carcinoma mouse model, berberine enhanced cisplatin efficacy, reduced tumor volume and cell counts, and ameliorated cisplatin-associated hepato-renal toxicity, alongside downregulation of Akt1, Axl, Mertk, and Gas6, indicating effects on the PI3K/Akt signaling pathway and efferocytosis.

Berberine also appeared in studies of inflammatory and infectious disease-related mechanisms. In a zebrafish model of TNBS-induced enteritis, berberine was identified among Huoxiang-Huanglian components predicted to bind ODC1, and the treatment was associated with reduced IL-1β, TNF-α, MDA, NLRP3, CASP1, NF-κB p65, and ODC1, while increasing IL-10, superoxide dismutase, and AhR expression. In a computational study of Coscinium fenestratum alkaloids against SARS-CoV-2 host factors, berberine was among the alkaloids considered in network pharmacology and docking analyses, although tembetarine emerged as the lead candidate rather than berberine.

Additional work has focused on formulation and comparative bioactivity. A liposomal release study compared two berberine-loaded liposomal formulations under controlled shear conditions and found that drug-membrane affinity influenced release under mild shear, while higher mechanical stress reduced formulation differences; the study also showed that a colloidal matrix could suppress release through a shear-shielding mechanism. In an anti-adipogenic phytochemical study, berberine served as the positive control against which a diarylpentanoid isolate was compared, with the isolate showing stronger inhibition of lipid accumulation in 3T3-L1 preadipocytes than berberine.